Já tu jen odložim citace na rakovinu
information on CBD, THC, and cancer:
Adinolfi, Barbara, et al. “Anticancer Activity of Anandamide in Human Cutaneous Melanoma Cells.” European Journal of Pharmacology, vol. 718, no. 1-3, 2013, pp. 154–159., doi:10.1016/j.ejphar.2013.08.039.
Anderson, Susan P., et al. “Impact of Medical Cannabis on Patient-Reported Symptoms for Patients with Cancer Enrolled in Minnesota’s Medical Cannabis Program.” Journal of Oncology Practice, 2019, doi:10.1200/jop.18.00562.
Aviello, Gabriella, et al. “Chemopreventive Effect of the Non-Psychotropic Phytocannabinoid Cannabidiol on Experimental Colon Cancer.” Journal of Molecular Medicine, vol. 90, no. 8, 2012, pp. 925–934., doi:10.1007/s00109-011-0856-x.
Bifulco, M., et al. “Endocannabinoids in Endocrine and Related Tumours.” Endocrine Related Cancer, vol. 15, no. 2, 2008, pp. 391–408., doi:10.1677/erc-07-0258.
Blasco-Benito, Sandra, et al. “Appraising the ‘Entourage Effect’: Antitumor Action of a Pure Cannabinoid versus a Botanical Drug Preparation in Preclinical Models of Breast Cancer.” Biochemical Pharmacology, vol. 157, 2018, pp. 285–293., doi:10.1016/j.bcp.2018.06.025
Brown, K J, et al. “Cannabidiol, a Novel Inverse Agonist for GPR12.” Biochemical and Biophysical Research Communications., vol. 4, no. 493, ser. 1, 4 Nov. 2017, pp. 451–454. 1, doi:10.1016/j.bbrc.2017.09.001.
Committee on the Health Effects of Marijuana. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. (A Report of the National Academies of Science, Engineering, and Medicine.) The National Academies Press, 2017.
Dall’ Stella, Paula B., et al. “Case Report: Clinical Outcome and Image Response of Two Patients with Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol.” Frontiers in Oncology, vol. 8, 2019, doi:10.3389/fonc.2018.00643.
Deng, L., et al. “Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture.” Journal of Pharmacology and Experimental Therapeutics, vol. 360, no. 1, 2016, pp. 215–224., doi:10.1124/jpet.116.236968.
Fisher, T, et al. “In Vitro and in Vivo Efficacy of Non-Psychoactive Cannabidiol in Neuroblastoma.” Current Oncology (Toronto, Ont.), Multimed Inc., Mar. 2016, www.ncbi.nlm.nih.gov/pmc/articles/PMC4791143/.
Guzman, M, et al. “A Pilot Clinical Study of Δ9-Tetrahydrocannabinol in Patients with Recurrent Glioblastoma Multiforme.” British Journal of Cancer, vol. 95, 17 July 2006, pp. 197–203.
Johnson, J R, et al. “Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain.” Journal of Pain Symptom Management, vol. 39, no. 2, Feb. 2010, pp. 167–179., doi:10.1016/j.jpainsymman.2009.06.008.
Ligresti, A. “Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma.” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 3, 2006, pp. 1375–1387., doi:10.1124/jpet.106.105247.
Marcu, J. P., et al. “Cannabidiol Enhances the Inhibitory Effects of 9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival.” Molecular Cancer Therapeutics, vol. 9, no. 1, 2010, pp. 180–189., doi:10.1158/1535-7163.mct-09-0407.
Massi, Paola, et al. “Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines.” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 3, 2003, pp. 838–845., doi:10.1124/jpet.103.061002.
Massi, Paola, et al. “Cannabidiol as Potential Anticancer Drug.” British Journal of Clinical Pharmacology, Blackwell Science Inc, Feb. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3579246/.
McAllister, Sean D., et al. “Cannabidiol as a Novel Inhibitor of Id-1 Gene Expression in Aggressive Breast Cancer Cells.” Molecular Cancer Therapeutics, vol. 6, no. 11, 2007, pp. 2921–2927., doi:10.1158/1535-7163.mct-07-0371.
McAllister, Sean D., et al. “Pathways Mediating the Effects of Cannabidiol on the Reduction of Breast Cancer Cell Proliferation, Invasion, and Metastasis.” Breast Cancer Research and Treatment, vol. 129, no. 1, 2010, pp. 37–47., doi:10.1007/s10549-010-1177-4.
McKallip, R. J. “Cannabidiol-Induced Apoptosis in Human Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of p22phox and Nox4 Expression.” Molecular Pharmacology, vol. 70, no. 3, 2006, pp. 897–908., doi:10.1124/mol.106.023937.
Nabissi, Massimo, et al. “Triggering of the TRPV2 Channel by Cannabidiol Sensitizes Glioblastoma Cells to Cytotoxic Chemotherapeutic Agents.” Carcinogenesis, vol. 34, no. 1, 2012, pp. 48–57., doi:10.1093/carcin/bgs328.
Pacher, Pál. “Towards the Use of Non-Psychoactive Cannabinoids for Prostate Cancer.” British Journal of Pharmacology, vol. 168, no. 1, 2012, pp. 76–78., doi:10.1111/j.1476-5381.2012.02121.x.
Pokrywka, M, et al. “Cannabinoids - a New Weapon against Cancer?” Postepy Hig Med Dosw (Online), vol. 70, 29 Dec. 2016, pp. 1309–1320., doi:10.5604/17322693.1227443.
Ramer, Robert, et al. “COX-2 and PPAR-g Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells.” Molecular Cancer Therapeutics, vol. 12, no. 1, 2012, pp. 69–82., doi:10.1158/1535-7163.mct-12-0335.
Ramer, Robert, and Burkhard, Hinz. “Antitumorigenic Targets of Cannabinoids – Current Status and Implications.” Expert Opinion on Therapeutic Targets, vol. 20, no. 10, 2016, pp. 1219–1235., doi:10.1080/14728222.2016.1177512.
Ramer, Robert, et al. “Cannabidiol Inhibits Cancer Cell Invasion via Upregulation of Tissue Inhibitor of Matrix Metalloproteinases-1.” Biochemical Pharmacology, U.S. National Library of Medicine, 1 Apr. 2010, www.ncbi.nlm.nih.gov/pubmed/19914218/.
Ramer, Robert, et al. “Cannabidiol Inhibits Lung Cancer Cell Invasion and Metastasis via Intercellular Adhesion Molecule-1.” The FASEB Journal, vol. 26, no. 4, 2012, pp. 1535–1548., doi:10.1096/fj.11-198184.
Rocha, Francisco Carlos Machado, et al. “Systematic Review of the Literature on Clinical and Experimental Trials on the Antitumor Effects of Cannabinoids in Gliomas.” Journal of Neuro-Oncology, vol. 116, no. 1, 2013, pp. 11–24., doi:10.1007/s11060-013-1277-1.
Russo, Ethan. “Cannabinoids in the Management of Difficult to Treat Pain.” Therapeutics and Clinical Risk Management, Volume 4, 2008, pp. 245–259., doi:10.2147/tcrm.s1928.
Russo, Ethan B., et al. “Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis-Based Medicine.” ChemInform, vol. 38, no. 47, 2007, doi:10.1002/chin.200747254.
Sharma, Manju, et al. “In Vitro Anticancer Activity of Plant-Derived Cannabidiol on Prostate Cancer Cell Lines.” Pharmacology & Pharmacy, vol. 05, no. 08, 2014, pp. 806–820., doi:10.4236/pp.2014.58091.
Shrivastava, A., et al. “Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-Talk between Apoptosis and Autophagy.” Molecular Cancer Therapeutics, vol. 10, no. 7, 2011, pp. 1161–1172., doi:10.1158/1535-7163.mct-10-1100.
Solinas, M, et al. “Cannabidiol Inhibits Angiogenesis by Multiple Mechanisms.” British Journal of Pharmacology, Blackwell Publishing Ltd, Nov. 2012, www.ncbi.nlm.nih.gov/pmc/articles/PMC3504989/.
Solinas, Marta, et al. “Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect.” PLoS ONE, vol. 8, no. 10, 2013, doi:10.1371/journal.pone.0076918.
Takeda, Shuso, et al. “Cannabidiolic Acid, a Major Cannabinoid in Fiber-Type Cannabis, Is an Inhibitor of MDA-MB-231 Breast Cancer Cell Migration.” Toxicology Letters, vol. 214, no. 3, 2012, pp. 314–319., doi:10.1016/j.toxlet.2012.08.029.
Vaccani, Angelo, et al. “Cannabidiol Inhibits Human Glioma Cell Migration through a Cannabinoid Receptor-Independent Mechanism.” British Journal of Pharmacology, vol. 144, no. 8, 2005, pp. 1032–1036., doi:10.1038/sj.bjp.0706134.
CBD for Diabetes: Participants taking CBD for diabetes were asked their average blood sugar levels before and after they started taking CBD. Though average blood sugar levels with CBD were still high, they showed significant improvements over the pre-CBD levels, decreasing from 178 to 130 on average. Participants also reported significant improvements in neuropathy-type symptoms (i.e. nerve pain, tingling or numbness), and some improvements in their ability to main